This study is for patients with stage II or III non-small cell lung cancer (NSCLC). It tests the safety and effectiveness of two treatments: hypofractionated radiation therapy and atezolizumab. Radiation therapy uses high-energy rays to kill cancer cells. Hypofractionated means giving higher doses over a shorter time. Atezolizumab is a type of immunotherapy, which helps the immune system fight cancer.

Patients will get radiation treatment five days a week for three weeks. Then, they will receive atezolizumab through an IV drip every 21 days for up to 12 months. The study checks for side effects and if the treatment stops cancer from growing or spreading.

• The study lasts up to three years, with follow-up visits after treatment.
• Participants must be 18 or older and not candidates for surgery or standard chemotherapy.
• Regular scans and blood tests will be part of the study.

Before joining, a patient will have tests to ensure they meet all requirements, including blood tests and scans. The study aims to understand how well these treatments work together and what side effects they might cause.